Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2 (Q69742375)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

title

Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

author name string

Naruo KI

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

Hinuma S

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

Shiho O

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

Houkan T

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

Ootsu K

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

Tsukamoto K

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

publication date

1 May 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Immunology

5 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

page(s)

278-283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2788049%20AND%20SRC:MED&resulttype=core&format=json

Comparison of the biological properties of purified natural and recombinant human interleukin-2.

5 October 2019

cites work

1 reference

12 December 2020

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1 reference

12 December 2020

Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages

1 reference

12 December 2020

Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

1 reference

12 December 2020

The immunological network at the site of tumor rejection

1 reference

12 December 2020

Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.

1 reference

12 December 2020

Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells

1 reference

12 December 2020

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

12 December 2020

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

1 reference

12 December 2020

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

12 December 2020

Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes

1 reference

12 December 2020

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

12 December 2020

Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report

1 reference

12 December 2020

Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells

1 reference

12 December 2020

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

12 December 2020

Systemic administration of recombinant human interleukin-2 in mice

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

Identifiers

1 reference